Targeting AMP deaminase 2 for ameliorating craving for sugar and other substances
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsRichard J Johnson, Ana Andres Hernando, Miguel A Lanaspa Garcia
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.
Claims4
A method for treating an AMPD2 related craving or addiction in a subject comprising administering a therapeutically effective amount of an AMPD2 inhibitor and/or a pan AMPD inhibitor, to the subject, wherein
- (a) the administering is done to decrease or treat a sugar, salt, or umami craving, or a combination thereof;
- (b) the administering is done to treat an addiction to alcohol, tobacco, nicotine, cocaine, methamphetamines, amphetamines and marijuana;
- (c) the administering is done to treat an addiction to opioids, cannabinoids, methylphenidate, phencyclidine, and substituted amphetamines, or sex;
- or
- (d) the administering is done to provide a diminished craving in the subject from at least one member selected from the group consisting of fructose, fructose-containing sugars, glucose, sucralose, and combinations thereof.
Dependencies are inferred from the claim text.